Volume 8, Number 12—December 2002
Research
Efficacy of Killed Virus Vaccine, Live Attenuated Chimeric Virus Vaccine, and Passive Immunization for Prevention of West Nile virus Encephalitis in Hamster Model
Table 1
Animal no. | HI antibody titer WNV antigen | CF antibody titer WNV antigenc | WNV PRN antibody titerd |
---|---|---|---|
H-8589 | 1:1280 | 1:320 | 1:10,240 |
H-8590 | 1:640 | 1:160 | 1:10,240 |
H-8591 | 1:640 | 1:320 | 1:5120 |
H-8592 | 1:640 | 1:80 | 1:2560 |
H-8593 | 1:640 | 1:160 | 1:2560 |
H-8594 | 1:1280 | 1:160 | 1:5120 |
H-8595 | 1:1280 | 1:320 | 1:10,240 |
H-8596 | 1:1280 | 1:320 | >1:20,480 |
H-8597 | 1:1280 | 1:320 | 1:5120 |
H-8598 | 1:1280 | 1:640 | 1:2560 |
aHI, hemagglutination inhibition; CF, complement fixation; PRN, plaque reduction neutralization; WNV, West Nile virus.
bAnimals 38 days after inoculation of virus strain NY385-99 (104.0 50% tissue culture infective dose50 given intraperitoneally).
cWNV antigen titer = >1:32.
dHighest serum dilution producing >90% plaque inhibition.
Page created: July 19, 2010
Page updated: July 19, 2010
Page reviewed: July 19, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.